328 related articles for article (PubMed ID: 31668326)
21. Treatment with Next-Generation ALK Inhibitors Fuels Plasma
Dagogo-Jack I; Rooney M; Lin JJ; Nagy RJ; Yeap BY; Hubbeling H; Chin E; Ackil J; Farago AF; Hata AN; Lennerz JK; Gainor JF; Lanman RB; Shaw AT
Clin Cancer Res; 2019 Nov; 25(22):6662-6670. PubMed ID: 31358542
[TBL] [Abstract][Full Text] [Related]
22. Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.
Ma X; Zhang K; Xu J; Gao H; Yang S; Qin H; Wang H; Gao F; Liu X
Thorac Cancer; 2023 Jul; 14(20):1980-1990. PubMed ID: 37265111
[TBL] [Abstract][Full Text] [Related]
23. Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer.
Umbela S; Ghacha S; Matuknauth R; Gause S; Joshee S; Deshmukh RR
Curr Probl Cancer; 2019 Dec; 43(6):100477. PubMed ID: 31109722
[TBL] [Abstract][Full Text] [Related]
24. Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.
Sakamoto MR; Honce JM; Lindquist DL; Camidge DR
Clin Lung Cancer; 2019 Mar; 20(2):e133-e136. PubMed ID: 30578110
[No Abstract] [Full Text] [Related]
25. Discovery of imidazo[1,2-b]pyridazine macrocyclic derivatives as novel ALK inhibitors capable of combating multiple resistant mutants.
Xiao X; Xu Y; Yu X; Chen Y; Zhao W; Xie Z; Zhu X; Xu H; Yang Y; Zhang P
Bioorg Med Chem Lett; 2023 Jun; 89():129309. PubMed ID: 37127101
[TBL] [Abstract][Full Text] [Related]
26. Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.
Ding M; Deng L; Yu R; Lu D; Bai Y; Wu X; Shao YW; Yang Y
Clin Lung Cancer; 2019 May; 20(3):e229-e232. PubMed ID: 30948231
[No Abstract] [Full Text] [Related]
27. Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Millett RL; Elkon JM; Tabbara IA
Anticancer Res; 2018 Sep; 38(9):4969-4975. PubMed ID: 30194140
[TBL] [Abstract][Full Text] [Related]
28. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Shiba-Ishii A; Johnson TW; Dagogo-Jack I; Mino-Kenudson M; Johnson TR; Wei P; Weinrich SL; McTigue MA; Walcott MA; Nguyen-Phuong L; Dionne K; Acker A; Kiedrowski LA; Do A; Peterson JL; Barth JL; Yeap BY; Gainor JF; Lin JJ; Yoda S; Hata AN
Nat Cancer; 2022 Jun; 3(6):710-722. PubMed ID: 35726063
[TBL] [Abstract][Full Text] [Related]
29. Brigatinib versus crizotinib for ALK-positive NSCLC.
Stirrups R
Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
[No Abstract] [Full Text] [Related]
30. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
[TBL] [Abstract][Full Text] [Related]
31. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.
Lin YT; Yu CJ; Yang JC; Shih JY
Clin Lung Cancer; 2016 Sep; 17(5):e77-e94. PubMed ID: 27130468
[TBL] [Abstract][Full Text] [Related]
32. Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure.
Fukuda A; Yoshida T
Expert Rev Anticancer Ther; 2023; 23(11):1157-1167. PubMed ID: 37772744
[TBL] [Abstract][Full Text] [Related]
33. Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.
Zhang X; Tong J; Wang T; Wang T; Xu L; Wang Z; Hou T; Pan P
Comput Biol Med; 2024 Feb; 169():107815. PubMed ID: 38128254
[TBL] [Abstract][Full Text] [Related]
34. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.
Passaro A; Prelaj A; Pochesci A; Spitaleri G; Rossi G; Del Signore E; Catania C; de Marinis F
Drugs Today (Barc); 2017 Aug; 53(8):435-446. PubMed ID: 29119148
[TBL] [Abstract][Full Text] [Related]
35. EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
Shen J; Meng Y; Wang K; Gao M; Du J; Wang J; Li Z; Zuo D; Wu Y
Cell Signal; 2022 Apr; 92():110264. PubMed ID: 35085771
[TBL] [Abstract][Full Text] [Related]
36. Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
Makimoto G; Ohashi K; Tomida S; Nishii K; Matsubara T; Kayatani H; Higo H; Ninomiya K; Sato A; Watanabe H; Kano H; Ninomiya T; Kubo T; Rai K; Ichihara E; Hotta K; Tabata M; Toyooka S; Takata M; Maeda Y; Kiura K
J Thorac Oncol; 2019 Nov; 14(11):2009-2018. PubMed ID: 31374369
[TBL] [Abstract][Full Text] [Related]
37. Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib.
Monzonís X; Arriola E
J Thorac Oncol; 2019 Nov; 14(11):e247-e248. PubMed ID: 31668321
[No Abstract] [Full Text] [Related]
38. An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer.
Hamilton G; Hochmair MJ
Expert Opin Pharmacother; 2019 Sep; 20(13):1551-1561. PubMed ID: 31328968
[No Abstract] [Full Text] [Related]
39. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Christopoulos P; Bozorgmehr F; Brückner L; Chung I; Krisam J; Schneider MA; Stenzinger A; Eickhoff R; Mueller DW; Thomas M
BMC Cancer; 2021 Jun; 21(1):743. PubMed ID: 34182952
[TBL] [Abstract][Full Text] [Related]
40. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
